Maribavir for Prevention of CMV After Stem Cell Transplants

A Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Assess the Safety, Tolerability, and Prophylactic Anti-cytomegalovirus Activity of Maribavir in Recipients of Allogeneic Stem Cell Transplants

Cytomegalovirus (CMV) infections remain a significant problem following various types of transplants that are associated with strong immunosuppressive therapy. Maribavir is a new oral anti-CMV drug with a novel mechanism of action compared to currently available anti-CMV drugs. This study will test the safety and anti-CMV activity of different doses of maribavir when given as CMV prophylaxis following stem cell transplants.

Inclusion Criteria:

• Allogeneic stem cell transplant recipient
• Recipient CMV seropositive
• Have transplant engraftment
• Able to swallow tablets

Exclusion Criteria:

• CMV organ disease
• HIV infection
• Use of other anti-CMV therapy post-transplant